-
GV1001 Peptide Shows Promise Against Neurodegeneration in Alzheimer’s Mouse Study
A peptide derived from human telomerase, GV1001, has been shown to rescue neurodegenerative changes in a mouse model of Alzheimer’s disease, offering a hopeful new direction for neuroprotective research.
-
FDA Advisory Panel Backs Expanded Access to Compounded Peptides
An FDA advisory panel has voted to add certain peptides to the agency’s approved list for pharmacy compounding, a move that could broaden patient access to these therapies through licensed compounding pharmacies.
-
FDA Panel Gives Nod to 6 Peptides, Signaling Path Forward for Access
An FDA advisory panel has voiced support for six peptide compounds, a step that could pave the way for expanded access and clearer regulatory standing for these popular compounds.
-
Peptide Vaccine SurVaxM Explored Alongside Chemotherapy for Newly Diagnosed Glioblastoma
A Phase II clinical trial is investigating whether combining the survivin-targeting peptide vaccine SurVaxM with standard chemotherapy can enhance the body’s immune response against glioblastoma tumors.
-
New Clinical Trial Explores Inhaled Epigenetic Therapy Combined With Immunotherapy for Early-Stage Lung Cancer
A new NIH trial is testing whether inhaled azacytidine, paired with standard chemotherapy and durvalumab, can improve pre-surgery treatment for operable early-stage non-small cell lung cancer.
-
New Phase I Trial Explores Bipolar Androgen Therapy for Advanced Prostate Cancer
A new phase I clinical trial is testing whether cycling testosterone levels—called bipolar androgen therapy—can help restore treatment sensitivity in patients with metastatic castration-resistant prostate cancer.
-
New Clinical Trial Explores Antibody-Drug Conjugate Combination for Advanced Cervical Cancer
A new international study is investigating whether pairing the antibody-drug conjugate sacituzumab tirumotecan with pembrolizumab, with or without bevacizumab, can improve outcomes for people with metastatic cervical cancer.
-
New Phase 2 Trial Launches to Target KRAS G12D-Mutated Pancreatic Cancer
A new Phase 2 study will evaluate VS-7375, alone and combined with cetuximab, in patients with metastatic KRAS G12D-mutated pancreatic cancer—a step forward for precision oncology in one of the hardest-to-treat cancers.
-
Peptide Vaccine PolyPEPI1018 Advances to Phase II Trial in Combination with Immunotherapy for Colorectal Cancer
A new phase II trial is underway to evaluate the peptide vaccine PolyPEPI1018 alongside the immunotherapy drug atezolizumab in patients with advanced colorectal cancer, marking a hopeful step for patients who have exhausted standard treatment options.
-
New Clinical Trial Explores Growth Hormone Therapy for Children with Achondroplasia
A new study is investigating the efficacy and safety of recombinant human growth hormone in children with achondroplasia, offering hope for expanded treatment options for this rare genetic condition.